Oncobiologics Issues $8.35 Million of Senior Secured Notes

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oncobiologics Issues $8.35 Million of Senior Secured Notes and Warrants to Acquire 1.9 Million Shares as part of Aggregate $10.0 Million Note and 2.3 Million Warrant Offering

CRANBURY, N.J., Dec. 23, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ: ONS ), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that it entered into a Note and Warrant Purchase Agreement with existing investors. 

The agreement provides for the issuance and sale of up to $10.0 million of senior secured promissory notes (the “Notes”), which bear interest at a rate of 5.0% per year and have a one-year maturity, and 5-year warrants to acquire an aggregate 2.3 million shares of the Company’s common stock at an exercise price of $3.00 per share (the “Warrants”).  At the initial closing, the Company issued $8.35 aggregate principal amount of Notes and 1,920,500 Warrants.  Under the agreement, the Company may issue up to $1.65 million of additional Notes and 379,500 Warrants in additional closings over 90 days from the date of the Note and Warrant Purchase Agreement without approval of holders of the Notes.

The Company used a portion of the proceeds from the sale of the Notes to pay off its existing senior secured bank loans, and will use the remainder for working capital purposes as it pursues strategic opportunities.   

This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Oncobiologics, Inc. and its BioSymphony™ Platform Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from an in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit  www.oncobiologics.com .

Forward-Looking Statements This press release contains forward-looking statements.  All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend” or “continue,” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning.  These include statements about the amount of additional senior notes and warrants we may issue. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Therefore, they may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

 

CONTACTS: Oncobiologics: Lawrence A. Kenyon Chief Financial Officer LawrenceKenyon@oncobiologics.com Media & Investors:         Alex Fudukidis Russo Partners, LLC alex.fudukidis@russopartnersllc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 25

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 142

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 115

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 150

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 81

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 177

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 98

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 115

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 83

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading

Top 5 Most Recently Viewed Articles

New Terminal One Partners with Plaza Premium to Elevate Travel

Updated Category News Views 234

New Terminal One & Plaza Premium Group Collaboration The New Terminal One at JFK International Airport has joined forces with Plaza Premium Group (PPG), a leading name in airport hospitality, to create two state-of-the-art lounges. Together, they aim to transform the travel experience at this vital international hub, covering close to 14,000 square feet and promising...

Continue Reading
Market Update: S&P 500 Fluctuates After Holiday Trading

Updated Category News Views 337

S&P 500 Experiences Mixed Results in Light Trading The recent trading session saw the S&P 500 close on a flat note after a day of ups and downs, all in the backdrop of lower-than-usual trading volumes, a trend typical of the holiday breakout. As of the market close, the S&P 500 had dipped by 0.1%, while the NASDAQ Composite mirrored this decrease. In contrast, the Dow...

Continue Reading
Brand Engagement Network Expands Horizons with Cataneo Acquisition

Updated Category News Views 104

Brand Engagement Network Expands Strategic Capabilities Jackson, Wyo. – brand Engagement Network, Inc. (NASDAQ: BNAI) has recently made headlines by agreeing to acquire a German media technology powerhouse, Cataneo Gmbh. This acquisition not only highlights BEN's commitment to growth but also demonstrates its ambition to transform how brands use AI to engage with their...

Continue Reading
Metagenomi Showcases Advanced Adenine Base Editors for Gene Therapy

Updated Category News Views 195

Introducing Metagenomi's Innovative Adenine Base Editors Metagenomi has unveiled its cutting-edge Adenine Base Editors (ABEs) at a recent event, highlighting their impressive capabilities in genome editing. These novel tools achieved over 95% targetability in gene modification, demonstrating exceptional performance and efficiency. Key Highlights from the Presentation...

Continue Reading
Streamlining IT Procurement: SysAid Launches on AWS Marketplace

Updated Category News Views 49

SysAid Now Accessible via AWS Marketplace SysAid, a leading Enterprise and IT Service Management solution provider, has made an exciting announcement regarding its availability on AWS Marketplace. This curated digital catalog is designed to simplify the process of discovering, procuring, and deploying software solutions. With AWS Marketplace having over 290,000 active...

Continue Reading